Aprea Therapeutics

Please email: rep@maximgrp.com To receive:  Maxim Group - Morning Minutes / Maxim Group - Equity Research Viking Therapeutics, Inc. (VKTX) covered by Naz Rahman, CFA & Jason McCarthy, Ph.D. Genelux Corporation (GNLX) covered by Jason McCarthy, Ph.D. & Michael Okunewitch Aprea Therapeutics, Inc. (APRE) covered by Jason McCarthy, Ph.D. & Michael Okunewitch Worksport Ltd (WKSP) covered by Tate Sullivan, CFA PainReform Ltd (PRFX) covered by Naz Rahman, CFA & Jason McCarthy, Ph.D. Please visit https://lnkd.in/egxnBQwJ for important disclosures.

Today, Aprea Therapeutics announced that preliminary safety results for its WEE1 inhibitor APR-1051 are highlighted in a poster presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain. Preliminary results demonstrate that APR-1051 is safe and well-tolerated at sub-therapeutic doses, with no hematologic toxicity. Preliminary efficacy data are expected in 2025. See the full news release for details: https://lnkd.in/e7PSWH9n Poster presentation: https://lnkd.in/eDgbygG3 #ENAsymp24 #CancerResearch EORTC - European Organisation for Research and Treatment of Cancer, American Association for Cancer Research, National Cancer Institute (NCI)

This week, Dr. Oren Gilad, CEO of Aprea Therapeutics, will participate in two presentations at the Maxim Healthcare Virtual Summit, taking place October 15-17, 2024. Register here for both the panel and fireside chat: https://lnkd.in/e_5buqAg See the news release for full details: https://lnkd.in/gfKSafDR

Team Aprea will be presenting four posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 - 25, 2024. See the news release for full poster details: https://lnkd.in/e3RFSbg7 #ENASymp24 is presented by EORTC - European Organisation for Research and Treatment of Cancer, American Association for Cancer Research , National Cancer Institute (NCI)

Aprea today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea’s potential best in class WEE1 inhibitor. “I am quite impressed by the progress the team has made advancing APR-1051, which has a differentiated profile, and is supported by compelling pre-clinical data. I am very excited to be associated with this program and I believe APR-1051 has the potential to be best in class,” said Dr. Pultar. See the full news release here: https://lnkd.in/edej3ZGT #news

Check out this interview with our CEO Oren Gilad to learn more about the work we’re doing at Aprea to develop targeted cancer therapies.

Oren Gilad, Ph.D., President & CEO of Aprea, recently spoke with Ira Pastor of the Progress, Potential, and Possibilities podcast. Listen to the full episode today to learn about the science behind Aprea’s platform technology and how harnessing the DNA damage response can allow us to develop targeted therapies with fewer side effects. Listen now: https://lnkd.in/ejE-g-Sr #Cancer #PrecisionMedicine

Check out this interview with Oren Gilad, Ph.D., President & CEO of Aprea, and Danny Levine of The Bio Report podcast to learn about the DNA damage response pathway, the possibility of harnessing synthetic lethality to treat cancers, and why Aprea’s approach to targeted therapies may result in safer treatments. Listen now: https://lnkd.in/eWeHk6V9 #Cancer #PrecisionMedicine

Oren Gilad, Ph.D., President & CEO of Aprea Therapeutics, will deliver a webcasted presentation and host one-on-one meetings in with investors at the Lytham Partners Fall 2024 Investor Conference, to take place virtually on Tuesday, October 1, 2024. The webcasted presentation will take place at 12:30 pm ET on Tuesday, October 1, 2024. Visit https://lnkd.in/emAtKR4z to access the webcast. See the full news release at: https://lnkd.in/eUetk3DH #InvestorPresentation #BusinessUpdate

Recently Oren Gilad, Ph.D., President and CEO, provided a business update for Aprea Therapeutics at the Life Sciences Investor Forum. A recording of the presentation is now available online. We invite individual and institutional investors, as well as advisors and analysts to review. Watch now: https://bit.ly/3zfRHLh #InvestorPresentation #BusinessUpdate